Reduced amyloid-β degradation in early Alzheimer's disease but not in the APPswePS1dE9 and 3xTg-AD mouse models

Aging Cell

Volumn 12, Issue 3, 2013, Pages 499-507

  Stargardt, Anita ^a   Gillis, Judith ^a   Kamphuis, Willem ^b   Wiemhoefer, Anne ^a   Kooijman, Lieneke ^b   Raspe, Marcel ^a   Benckhuijsen, Willemien ^c   Drijfhout, Jan W ^c   M Hol, Elly ^b,d   Reits, Eric ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

3xTg AD; Alzheimer; Amyloid; APPswePS1dE9; Insulin degrading enzyme

Indexed keywords

AMYLOID BETA PROTEIN; PEPTIDASE; PROTEINASE INHIBITOR;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN HEK293; CYTOSOLIC FRACTION; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; MOUSE; NONHUMAN; OLIGOMERIZATION; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN ISOLATION; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; INSULYSIN; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PEPTIDE HYDROLASES; RNA, MESSENGER;

MUS;

EID: 84877805144     PISSN: 14749718     EISSN: 14749726     Source Type: Journal    
DOI: 10.1111/acel.12074     Document Type: Article

References (50)

1. Bayer TA, Wirths O (2010) Intracellular accumulation of amyloid-beta-a predictor for synaptic dysfunction and neuron loss in Alzheimer's disease. Front. Aging. Neurosci., Frontiers Research Foundation 2, 8.
2. Bertram L, Lill CM, Tanzi RE (2010) The genetics of Alzheimer disease: back to the future. Neuron 68, 270-281.
3. Bossers K, Wirz KT, Meerhoff GF, Essing AH, van Dongen JW, Houba P, Kruse CG, Verhaagen J, Swaab DF (2010) Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease. Brain 133, 3699-3723.
4. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239-259.
5. Bückig A, Tikkanen R, Herzog V, Schmitz A (2002) Cytosolic and nuclear aggregation of the amyloid ß-peptide following its expression in the endoplasmic reticulum. Histochem. Cell Biol., Springer 118, 353-360.
6. Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM (2005) Age-and region-dependent alterations in Aβ-degrading enzymes: implications for Aβ-induced disorders. Neurobiol. Aging, Elsevier 26, 645-654.
7. Chesneau V, Perlman RK, Li W, Keller GA, Rosner MR (1997) Insulin-degrading enzyme does not require peroxisomal localization for insulin degradation. Endocrinology 138, 3444-3451.
8. Chesneau V, Vekrellis K, Rosner M, Selkoe D (2000) Purified recombinant insulin-degrading enzyme degrades amyloid beta-protein but does not promote its oligomerization. Biochem. J., Portland Press Ltd 351, 509.
9. Dorfman VB, Pasquini L, Riudavets M, López-Costa JJ, Villegas A, Troncoso JC, Lopera F, Castaño EM, Morelli L (2010) Differential cerebral deposition of IDE and NEP in sporadic and familial Alzheimer's disease. Neurobiol. Aging 31, 1743-1757.
10. Guo Q, Manolopoulou M, Bian Y, Schilling AB, Tang W (2010) Molecular basis for the recognition and cleavages of IGF-II, TGF-α, and amylin by human insulin-degrading enzyme. Trends Pharmacol. Sci., Elsevier 395, 430-443.
11. Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Science 12, 383.
12. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, American Association for the Advancement of Science 297, 353-356.
13. Huitinga I, Rademaker M, Klioueva N (2008) The art of brain banking in Europe: ethical, legal and practical guidelines for donor recruitment, tissue handling and tissue distribution. J. Neural Transm. 115, 1715.
14. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL (2004) Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase. Hum. Mol. Genet., Oxford Univ Press 13, 159-170.
15. Jiang Q, Lee CYD, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE (2008) ApoE promotes the proteolytic degradation of Aβ. Neuron 58, 681-693.
16. Kamphuis W, Mamber C, Moeton M, Kooijman L, Sluijs JA, Jansen AHP, Verveer M, de Groot LR, Smith BD, Rangarajan S, Rodríguez JJ, Orre M, Hol EM (2012) GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease. PLoS One 7, e42823.
17. Kamphuis W, Orre AM, Kooijman L, Dahmen M, Hol EM (2012) Differential cell proliferation in the cortex of the APPswePS1dE9 Alzheimer's disease mouse model. Glia 60, 615-629.
18. Kurochkin IV, Goto S (1994) Alzheimer's β-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett. 345, 33-37.
19. LaFerla FM, Oddo S (2005) Alzheimer's disease: Aβ, tau and synaptic dysfunction. Trends Mol. Med. 11, 170-176.
20. LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci. 8, 499-509.
21. Lee EK, Park YW, Shin DY, Mook-Jung I, Yoo YJ (2006) Cytosolic amyloid-β peptide 42 escaping from degradation induces cell death. Biochem. Biophys. Res. Commun., Elsevier 344, 471-477.
22. Li M, Chen L, Lee DHS, Yu LC, Zhang Y (2007) The role of intracellular amyloid [beta] in Alzheimer's disease. Prog. Neurobiol., Elsevier 83, 131-139.
23. Matsui T, Ingelsson M, Fukumoto H, Ramasamy K, Kowa H, Frosch MP, Irizarry MC, Hyman BT (2007) Expression of APP pathway mRNAs and proteins in Alzheimer's disease. Brain Res., Elsevier 1161, 116-123.
24. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330, 1774.
25. Murrell J, Farlow M, Ghetti B, Benson MD (1991) A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science, American Association for the Advancement of Science 254, 97-99.
26. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG (2001) The'Arctic'APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation. Nat. Neurosci., Nature Publishing Group 4, 887-893.
27. O'Brien RJ, Wong PC (2011) Amyloid precursor protein processing and Alzheimer's disease. Annu. Rev. Neurosci. 34, 185-204.
28. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM (2003a) Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging, Elsevier 24, 1063-1070.
29. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003b) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron, Elsevier 39, 409-421.
30. Oksman M, Iivonen H, Hogyes E, Amtul Z, Penke B, Leenders I, Broersen L, Lütjohann D, Hartmann T, Tanila H (2006) Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol. Dis., Elsevier 23, 563-572.
31. Pérez A, Morelli L, Cresto JC, Castaño EM (2000) Degradation of soluble amyloid β-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem. Res., Springer 25, 247-255.
32. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ (1998) Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J. Biol. Chem. 273, 32730-32738.
33. Querfurth HW, LaFerla FM (2010) Alzheimer's disease. N. Engl. J. Med. 362, 329-344.
34. Reits E, Neijssen J, Herberts C, Benckhuijsen W, Janssen L, Drijfhout JW, Neefjes J (2004) A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity, Elsevier 20, 495-506.
35. Roher AE, Esh CL, Kokjohn TA, Castaño EM, Van Vickle GD, Kalback WM, Patton RL, Luehrs DC, Daugs ID, Kuo Y, Emmerling MR, Soares H, Quinn JF, Kaye J, Connor DJ, Silverberg NB, Adler CH, Seward JD, Beach TG, Sabbagh MN (2009) Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers. Dement. 5, 18-29.
36. Rossler M, Zarski R, Bohl J, Ohm TG (2004) Stage-dependent and sector-specific neuronal loss in hippocampus during Alzheimer's disease. Acta Neuropathol. 103, 363-369.
37. Schmitz A, Schneider A, Kummer MP, Herzog V (2004) Endoplasmic reticulum-localized amyloid β-peptide is degraded in the cytosol by two distinct degradation pathways. Traffic, Wiley Online Library 5, 89-101.
38. Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741-766.
39. Song S, Lee H, Kam TI, Tai ML, Lee JY, Noh JY, Shim SM, Seo SJ, Kong YY, Nakagawa T (2008) E2-25K/Hip-2 regulates caspase-12 in ER stress-mediated Aβ neurotoxicity. J. Cell. Biol., Rockefeller Univ Press 182, 675-684.
40. Tam JH, Pasternak SH (2012) Amyloid and Alzheimer's disease: inside and out. Can. J. Neurol. Sci. 39, 286-298.
41. Thinakaran G, Koo EH (2008) Amyloid precursor protein trafficking, processing, and function. J. Biol. Chem. 283, 29615-29619.
42. Tjernberg LO, Naslund J, Lindqvist F, Johansson J, Karlstrom AR, Thyberg J, Terenius L, Nordstedt C (1996) Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J. Biol. Chem. 271, 8545-8548.
43. Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, Rosner MR, Selkoe DJ (2000) Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J. Neurosci. 20, 1657-1665.
44. Wang S, Wang R, Chen L, Bennett DA, Dickson DW, Wang DS (2010) Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain. J. Neurochem., Wiley Online Library 115, 47-57.
45. Wirths O, Bayer TA (2010) Neuron loss in transgenic mouse models of Alzheimer's disease. Int. J. Alzheimers Dis. 2010, 723782.
46. Wirths O, Multhaup G, Czech C, Blanchard V, Moussaoui S, Tremp G, Pradier L, Beyreuther K, Bayer TA (2001) Intraneuronal Aβ accumulation precedes plaque formation in β-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci. Lett., 306, 116-120.
47. Yan P, Bero AW, Cirrito JR, Xiao Q, Hu X, Wang Y, Gonzales E, Holtzman DM, Lee JM (2009) Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J. Neurosci. 29, 10706-10714.
48. Yang AJ, Chandswangbhuvana D, Margol L, Glabe CG (1998) Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Aβ1-42 pathogenesis. J. Neurosci. Res., Wiley Online Library 52, 691-698.
49. Youmans KL, Tai LM, Kanekiyo T, Stine WB Jr, Michon SC, Nwabuisi-Heath E, Manelli A, Fu Y, Riordan S, Eimer WA (2012) Intraneuronal Abeta detection in 5xFAD mice by a new Abeta-specific antibody. Mol. Neurodegener., BioMed Central Ltd 7, 8.
50. Zhao Z, Xiang Z, Haroutunian V, Buxbaum JD, Stetka B, Pasinetti GM (2007) Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease. Neurobiol. Aging, Elsevier 28, 824-830.